Abstract 2270
Background
Despite a population of over 180 million and over 115,950 new cases of cancer diagnosed every year, Nigeria has no dedicated medical oncologists (MO). Most oncology care is delivered through surgical (SO) and radiation oncologists (RO) who number less than 50 in the entire country. With the limited number of oncology professionals, cancer patients experience poor outcomes, with a less than 10% of 5-year cancer survival rate.
Methods
The participants were nominated by their institutions to attend the medical oncology training. Through the support of FSP and U.S. Embassy in Nigeria, MGM and TOC delivered 10-days of lectures based on ASCO, ESMO and NCCN guidelines in Abuja, Nigeria. Participants represented 15 Nigerian states, including 5 of the 6 ethnic and geographic regions. Mean correct scores of participants that completed both the pre- and post-course 25 question tests (composed by 2 of the authors TOC and MGM) were compared using GraphPad Prism 7.0a by Paired t-tests.
Results
Forty-four oncologists were identified of which 11 (25%) were females. Twenty-five (57%) completed both the pre- and post-tests and fully participated in the 10-day lecture series. 12 participates that completed the training were residents and 12 were attending physicians. One doctor did not identify as a resident or attending. Of the 25 that completed both tests, percentage of correct answers increased from 45% to 59% (2-sided p-value <0.0001). Benefits were seen both with attending doctors 45% to 59% (p = 0.0046) and resident doctors 45% to 59% (0.0007).
Conclusions
MO education coordinated by FSP and PPB improved MO knowledge in Nigeria regardless of participant background. Similar models may be employed across Sub-Saharan Africa. Reasons for lost participation need to be defined.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Project PinkBlue.
Funding
United States of America Department of State.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract